It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Dysfunction of adipocytes and adipose tissue is a primary defect in obesity and obesity-associated metabolic diseases. Interferon regulatory factor 3 (IRF3) has been implicated in adipogenesis. However, the role of IRF3 in obesity and obesity-associated disorders remains unclear. Here, we show that IRF3 expression in human adipose tissues is positively associated with insulin sensitivity and negatively associated with type 2 diabetes. In mouse pre-adipocytes, deficiency of IRF3 results in increased expression of PPARγ and PPARγ-mediated adipogenic genes, leading to increased adipogenesis and altered adipocyte functionality. The IRF3 knockout (KO) mice develop obesity, insulin resistance, glucose intolerance, and eventually type 2 diabetes with aging, which is associated with the development of white adipose tissue (WAT) inflammation. Increased macrophage accumulation with M1 phenotype which is due to the loss of IFNβ-mediated IL-10 expression is observed in WAT of the KO mice compared to that in wild-type mice. Bone-marrow reconstitution experiments demonstrate that the nonhematopoietic cells are the primary contributors to the development of obesity and both hematopoietic and nonhematopoietic cells contribute to the development of obesity-related complications in IRF3 KO mice. This study demonstrates that IRF3 regulates the biology of multiple cell types including adipocytes and macrophages to prevent the development of obesity and obesity-related complications and hence, could be a potential target for therapeutic interventions for the prevention and treatment of obesity-associated metabolic disorders.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 National University of Singapore, Department of Microbiology & Immunology, and NUSMED Immunology Translational Research Programme,Yong Loo Lin School of Medicine, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431); National University of Singapore, Immunology Programme, Life Sciences Institute, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
2 University of Cambridge, Addenbrooke’s Hospital, Institute of Metabolic Science, Wellcome Trust-MRC MDU Metabolic Disease Unit, Cambridge, UK (GRID:grid.120073.7) (ISNI:0000 0004 0622 5016)
3 National University of Singapore, Cancer Science Institute of Singapore, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
4 Endocrinology and Nutrition, Institut d’Investigacio Biomedica de Girona (IDIBGI), CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn, CB06/03/010), Instituto de Salud Carlos III, and Department of Medical Sciences, Faculty of Medicine, Department of Diabetes, Girona, Spain (GRID:grid.429182.4)
5 National University Hospital, Department of Surgery, Singapore, Singapore (GRID:grid.412106.0) (ISNI:0000 0004 0621 9599)